- Home
- CELZ vs RNAZ Comparison
CELZ vs RNAZ Comparison
Compare CELZ & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- RNAZ
- Stock Information
- Founded
- CELZ 1998
- RNAZ 2016
- Country
- CELZ United States
- RNAZ United States
- Employees
- CELZ N/A
- RNAZ N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- RNAZ Health Care
- Exchange
- CELZ Nasdaq
- RNAZ Nasdaq
- Market Cap
- CELZ 7.4M
- RNAZ 6.1M
- IPO Year
- CELZ N/A
- RNAZ 2021
- Fundamental
- Price
- CELZ $3.31
- RNAZ $10.97
- Analyst Decision
- CELZ
- RNAZ Strong Buy
- Analyst Count
- CELZ 0
- RNAZ 1
- Target Price
- CELZ N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- CELZ 128.9K
- RNAZ 14.3K
- Earning Date
- CELZ 11-07-2025
- RNAZ 08-14-2025
- Dividend Yield
- CELZ N/A
- RNAZ N/A
- EPS Growth
- CELZ N/A
- RNAZ N/A
- EPS
- CELZ N/A
- RNAZ N/A
- Revenue
- CELZ $6,000.00
- RNAZ N/A
- Revenue This Year
- CELZ N/A
- RNAZ N/A
- Revenue Next Year
- CELZ N/A
- RNAZ N/A
- P/E Ratio
- CELZ N/A
- RNAZ N/A
- Revenue Growth
- CELZ N/A
- RNAZ N/A
- 52 Week Low
- CELZ $1.69
- RNAZ $6.15
- 52 Week High
- CELZ $6.90
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- CELZ 57.11
- RNAZ 55.77
- Support Level
- CELZ $3.09
- RNAZ $9.29
- Resistance Level
- CELZ $3.37
- RNAZ $10.48
- Average True Range (ATR)
- CELZ 0.17
- RNAZ 0.66
- MACD
- CELZ -0.00
- RNAZ 0.02
- Stochastic Oscillator
- CELZ 73.19
- RNAZ 100.00
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.